FDA Approved: EVRYSDI — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Evrysdi (risdiplam) submitted by Genentech, Inc., under NDA 213535.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• EVRYSDI (risdiplam)

Snippet

SUPPL AP for EVRYSDI (RISDIPLAM)